文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

美国医疗保险受益人中下腔静脉滤器的上市后监测:SAFE-IVC研究

Postmarketing Surveillance of Inferior Vena Cava Filters Among US Medicare Beneficiaries: The SAFE-IVC Study.
PubMed 文献 · JAMA · 2024-01-01
一句话结论2013至2021年美国老年患者下腔静脉滤器置入量下降,但回收率仍低(中位1.2年累积15.3%),未回收滤器可能带来长期并发症。

该研究为预设的回顾性观察性队列,利用2013年1月1日至2021年12月31日美国医疗保险按服务付费(FFS)受益人100%的住院和门诊索赔数据,纳入首次置入下腔静脉滤器的270866例患者(平均年龄75.1岁,52.8%女性)。滤器置入量从2013年每年44680例降至2021年每年19501例;回收累积发生率在中位1.2年时为15.3%,最长随访9.0年时为16.8%。未回收滤器患者腔静脉血栓和深静脉血栓发生率分别为2.2%(95%CI 2.1%-2.3%)和9.2%(95%CI 9.0%-9.3%);回收尝试成功率为93.5%,30天并发症发生率低。作者认为需要策略提高及时回收率。

要点

  • 2013至2021年下腔静脉滤器置入量从每年44680例降至19501例,但回收率仍低:中位1.2年累积回收率15.3%,最长随访9.0年16.8%。
  • 未回收滤器患者腔静脉血栓发生率为2.2%(95%CI 2.1%-2.3%),深静脉血栓发生率为9.2%(95%CI 9.0%-9.3%)。
  • 回收尝试成功率为93.5%,30天死亡率0.7%(95%CI 0.6%-0.8%),滤器相关并发症1.4%(95%CI 1.2%-1.5%)。
  • 高龄、更多合并症和黑人种族与回收可能性降低相关,大型教学医院置入与回收可能性增加相关。
  • 63.3%的患者在滤器置入30天内有大出血或创伤;64.9%因首次静脉血栓栓塞症置入,26.3%因复发性静脉血栓栓塞症,8.8%为静脉血栓栓塞症预防。

适用人群与场景

  • 美国医疗保险按服务付费(FFS)受益人,2013年1月1日至2021年12月31日期间首次置入下腔静脉滤器,平均年龄75.1岁,52.8%女性。
  • 64.9%因首次静脉血栓栓塞症置入,26.3%因复发性静脉血栓栓塞症,8.8%为静脉血栓栓塞症预防。
  • 63.3%在滤器置入30天内有大出血或创伤。

研究设计与关键结果

  • 研究类型:预设的回顾性观察性队列,利用美国医疗保险FFS受益人100%的住院和门诊索赔数据,纳入270866例首次置入下腔静脉滤器的患者。
  • 滤器置入量从2013年每年44680例降至2021年每年19501例。
  • 回收累积发生率:中位1.2年时为15.3%,最长随访9.0年时为16.8%。
  • 高龄、更多合并症和黑人种族与回收可能性降低相关;大型教学医院置入与回收可能性增加相关。
  • 未回收滤器患者腔静脉血栓发生率为2.2%(95%CI 2.1%-2.3%),深静脉血栓发生率为9.2%(95%CI 9.0%-9.3%)。
  • 回收尝试成功率为93.5%,30天并发症:死亡率0.7%(95%CI 0.6%-0.8%),滤器相关并发症1.4%(95%CI 1.2%-1.5%)。

证据类型、等级与局限

  • 证据类型:回顾性观察性队列研究(基于索赔数据)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,需要策略提高及时回收率,因为未回收的下腔静脉滤器可能存在长期并发症。
  • 当前专业学会和美国食品药品监督管理局的建议认可在临床可行时及时回收下腔静脉滤器。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Inferior vena cava filters (IVCFs) are commonly used to prevent pulmonary embolism in selected clinical scenarios, despite limited evidence to support their use. Current recommendations from professional societies and the US Food and Drug Administration endorse timely IVCF retrieval when clinically feasible. Current IVCF treatment patterns and outcomes remain poorly described.

OBJECTIVES: To evaluate temporal trends and practice patterns in IVCF insertion and retrieval among older US patients and report the incidence of periprocedural and long-term safety events of indwelling and retrieved IVCFs.

DESIGN, SETTING, AND PARTICIPANTS: Prespecified, retrospective, observational cohort of Medicare Fee-for-Service (FFS) beneficiaries, leveraging 100% of samples of inpatient and outpatient claims data from January 1, 2013, to December 31, 2021.

EXPOSURE: First-time IVCF insertion while insured by Medicare FFS.

MAIN OUTCOMES AND MEASURES: The primary safety outcome was the composite of all-cause death, filter-related complications (eg, fracture, embolization), operating room visits following filter-related procedures, or new diagnosis of deep vein thrombosis (DVT). Events were considered periprocedural if they occurred within 30 days of IVCF insertion or retrieval and long-term if they occurred more than 30 days after.

RESULTS: Among 270 866 patients with IVCFs placed during the study period (mean age, 75.1 years; 52.8% female), 64.9% were inserted for first-time venous thromboembolism (VTE), 26.3% for recurrent VTE, and 8.8% for VTE prophylaxis. Of these patients, 63.3% had major bleeds or trauma within 30 days of IVCF insertion. The volume of insertions decreased from 44 680 per year in 2013 to 19 501 per year in 2021. The cumulative incidence of retrieval was 15.3% at a median of 1.2 years and 16.8% at maximum follow-up of 9.0 years. Older age, more comorbidities, and Black race were associated with a decreased likelihood of retrieval, whereas placement at a large teaching hospital was associated with an increased likelihood of retrieval. The incidence of caval thrombosis and DVT among patients with nonretrieved IVCFs was 2.2% (95% CI, 2.1%-2.3%) and 9.2% (95% CI, 9.0%-9.3%), respectively. The majority (93.5%) of retrieval attempts were successful, with low incidence of 30-day complications (mortality, 0.7% [95% CI, 0.6%-0.8%]; filter-related complications, 1.4% [95% CI, 1.2%-1.5%]).

CONCLUSIONS AND RELEVANCE: In this large, US real-world analysis, IVCF insertion declined, yet retrievals remained low. Strategies to increase timely retrieval are needed, as nonretrieved IVCFs may have long-term complications.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Ferro EG, Mackel JB, Kramer RD, et al. Postmarketing Surveillance of Inferior Vena Cava Filters Among US Medicare Beneficiaries: The SAFE-IVC Study. JAMA. 2024. PMID: 39504004. doi:10.1001/jama.2024.19553

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。